Xilio Therapeutics (XLO) to Release Earnings on Thursday

Xilio Therapeutics (NASDAQ:XLO) is projected to release its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Xilio Therapeutics to post earnings of ($0.03) per share for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 13, 2025 at 9:00 AM ET.

Xilio Therapeutics (NASDAQ:XLO) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Xilio Therapeutics had a negative net margin of 374.79% and a negative return on equity of 399.15%. The business had revenue of $8.21 million during the quarter, compared to analysts’ expectations of $8.21 million. On average, analysts expect Xilio Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Xilio Therapeutics Stock Up 6.7%

Shares of Xilio Therapeutics stock opened at $0.85 on Tuesday. Xilio Therapeutics has a twelve month low of $0.62 and a twelve month high of $1.70. The business has a 50-day moving average price of $0.77 and a 200 day moving average price of $0.75. The firm has a market cap of $44.05 million, a PE ratio of -1.12 and a beta of -0.08.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Wall Street Zen lowered Xilio Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 16th. Leerink Partners assumed coverage on Xilio Therapeutics in a research note on Wednesday, August 6th. They set an “outperform” rating and a $2.00 price objective for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Xilio Therapeutics in a research note on Wednesday, October 8th. Finally, Leerink Partnrs upgraded Xilio Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $3.00.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.